Yes
Yes
Publications
112
Total Publications
42
Abstract/Manuscript
10
Oral Presentation
60
Poster Presentation
2026 · Poster Presentation · AbbVie Inc. · Dermatology
Characterization of patient perception of odor severity in hidradenitis suppurativa using TARGET-DERM HS
Read more →2026 · Poster Presentation · University of Alabama Birmingham · Dermatology
Healthcare Disparities in Hidradenitis Suppurativa in the US: TARGET-DERM HS
Read more →2025 · Poster Presentation · Genentech · Hepatology
Real world treatment patterns and outcomes for hepatocellular carcinoma (HCC) patients receiving transarterial chemoembolization (TACE) or transarterial radioembolization (TARE) in the TARGET-HCC registry
Read more →2025 · Poster Presentation · Merck · Hepatology
Real-World Treatment Patterns Among US Adults with Unresectable Hepatocellular Carcinoma (HCC) Eligible For Locoregional Therapy (LRT)
Read more →2025 · Poster Presentation · AbbVie Inc. · Dermatology
Correlation between achieving SALT 20 score and clinician- and patient-reported outcomes among patients diagnosed with alopecia areata in the US: An assessment from the TARGET-DERM AA registry
Read more →2025 · Poster Presentation · Northwestern University · Dermatology
Race and ethnicity sub-groups of alopecia areata patients have differing clinical characteristics: TARGET-DERM AA
Read more →2025 · Poster Presentation · AbbVie Inc. · Dermatology
Generic vs. disease-specific patient reported outcome (PRO) instruments for assessing HRQoL burden among patients diagnosed with alopecia areata: Evidence from TARGET-DERM AA
Read more →2025 · Poster Presentation · Methods/Pharmacoepi
Power Vs. Precision When Estimating Risk Differences Using Observational Data? A Case Study From TARGET-IBD
Read more →2025 · Abstract/Manuscript · UNC
The Magnitude of Polypharmacy and Role of Disease Severity and Patient Sex in Medication Use Among Patients With MASLD Enrolled in TARGET-NASH
Read more →2025 · Abstract/Manuscript · Kings College of London
Cardiovascular risk assessment tools are insufficient for patients with metabolic dysfunction associated steatotic liver disease
Read more →2025 · Abstract/Manuscript
DAA-PASS: A Prospective Evaluation of HCC Recurrence After Direct Acting Antiviral Therapy
Read more →2025 · Poster Presentation · University of Miami (FL) · Hepatology
Changes in The Fibrosis-4 (FIB-4) Score Accurately Reflects The Disease Trajectory of Metabolic Dysfunction Associated Steatotic Liver Disease
Read more →2025 · Poster Presentation · Saint Louis University · Hepatology
Clinical Characteristics of Patients With Presumed MASLD Who Meet Met-ALD Criteria in the TARGET-NASH Cohort
Read more →2025 · Poster Presentation · Madrigal · Hepatology
Relationship between non-invasive tests, clinical outcomes and liver biopsy among people with MASH under real-world conditions
Read more →2025 · Poster Presentation · German Diabetes Center (DDZ) / Heinrich Heine University Düsseldorf · Hepatology
Type 2 Diabetes and Obesity are The Main Metabolic Risk Factors for The Development of Cirrhosis in People with Metabolic Dysfunction Associated Steatohepatitis
Read more →2025 · Abstract/Manuscript · Northwestern University
Unmet Needs of Effective Advanced Systemic Therapies in Moderate-to-Severe Atopic Dermatitis Patients in the TARGET-DERM AD Registry
Read more →2025 · Abstract/Manuscript · University of North Carolina at Chapel Hill
Leveraging public health infrastructures to support sexual health for women living in the Southern United States
Read more →2024 · Poster Presentation · German Diabetes Center (DDZ) / Heinrich Heine University Düsseldorf · Hepatology
Type 2 diabetes increases the risk of progression to metabolic dysfunction-associated steatohepatitis-related cirrhosis in a real world setting
Read more →2024 · Poster Presentation · University of Birmingham UK · Hepatology
Stability of the NASH-CHECK patient-reported outcome measure over time in patients with metabolic dysfunction-associated steatotic liver disease and stable clinical status
Read more →2024 · Poster Presentation · UNC · Hepatology
A prospective assessment of the impact of decompensation of cirrhosis on patient-reported outcomes in metabolic dysfunction-associated steatotic liver disease
Read more →2024 · Poster Presentation · Merck · Hepatology
Time to Disease Progression and All-Cause Mortality in Adult MASH Patients in Real-World US Cohort
Read more →2024 · Poster Presentation · Merck · Hepatology
Characteristics of adult MASH patients and factors associated with MASH-relevant clinical endpoints in a real-world US cohort
Read more →2024 · Poster Presentation · Novo Nordisk · Hepatology
Understanding Metabolic Dysfunction-Associated Steatohepatitis: Differences in Clinical and Demographic Characteristics Across Racial and Ethnic Groups
Read more →2024 · Poster Presentation · UNC · Hepatology
Use of sodium-glucose transport protein 2 inhibitors and dipeptidyl peptidase 4 inhibitors in patients with MASLD in a real-world setting is associated with lower all-cause mortality
Read more →2024 · Poster Presentation · University of Birmingham UK · Hepatology
Real-World Use of Glucagon-Like Peptide 1 Receptor Agonists in Patients with MASLD: A Cross-Sectional Analysis from TARGET-NASH
Read more →2024 · Poster Presentation · Saint Louis University · Hepatology
A prospective assessment of disease progression impact on patient-reported outcomes in metabolic dysfunction-associated steatotic liver disease
Read more →2024 · Poster Presentation · Madrigal · Hepatology
Non-invasive tests as a prediction tool to assess MASH resolution score
Read more →2024 · Poster Presentation · Madrigal · Hepatology
A longitudinal assessment of cardiovascular risk for NASH/MASH patients enrolled in TARGET-NASH
Read more →2024 · Poster Presentation · University of Miami (FL) · Hepatology
Complication-Free Survival in a Real-World Cohort of PBC Patients: Deep Versus Adequate ALP Response to UDCA
Read more →2024 · Poster Presentation · Medical University of South Carolina · Dermatology
Demographics and disease characteristics of patients with alopecia areata with comorbid atopic dermatitis, vitiligo or anxiety/depression: TARGET-DERM AA
Read more →2024 · Poster Presentation · George Washington University · Dermatology
Why Do Optimal Targets for Itch and Skin Clearance Matter in Atopic Dermatitis Treatment? Insights from the TARGET-DERM AD Registry
Read more →2024 · Poster Presentation · Novartis AG · Dermatology
Real-world study of hidradenitis suppurativa: skin lesions and pain are associated with Hurley Stage in TARGET-DERM HS
Read more →2024 · Poster Presentation · Wake Forest University School of Medicine · Gastroenterology
Predictors of Patients Receiving No Medication for Treatment of Eosinophilic Esophagitis in the United States: Data from the TARGET-EGIDS Cohort
Read more →2024 · Poster Presentation · Wake Forest University School of Medicine · Gastroenterology
Time to Diagnosis Among Patients with Eosinophilic Esophagitis in the United States
Read more →2024 · Poster Presentation · Merck & Co. · Methods/Pharmacoepi
Assessing The Value Of Linking Abstracted Medical Record Data With Administrative Claims Data To Study Patients With High-Risk Non-Muscle Invasive Bladder Cancer In The United States
Read more →2024 · Abstract/Manuscript · Duke
Concordance of MASLD and NAFLD nomenclature in youth participating in the TARGET-NASH real-world cohort
Read more →2024 · Abstract/Manuscript · Heinrich Heine University Dusseldorf/German Diabetes Center
High Concordance Between Nonalcoholic Fatty Liver Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease in the TARGET-NASH Real-World Cohort
Read more →2024 · Poster Presentation · Heinrich Heine University Düsseldorf · Hepatology
Relationship between liver biopsy fibrosis stage and clinical outcomes among persons with MASLD/MASH
Read more →2024 · Oral Presentation · Saint Louis University · Hepatology
Use of glucagon-like peptide 1 receptor agonists in patients with MASLD in a real-world setting is associated with slower disease progression and lower all-cause mortality
Read more →2024 · Oral Presentation · Novartis AG · Dermatology
Patient reported burden is associated with clinician-reported severity in alopecia areata: Real world insights from TARGET-DERM AA
Read more →2024 · Abstract/Manuscript · University of North Carolina at Chapel Hill
Factors Predicting Loss of Remission in Crohn's Disease Patients in Endoscopic Remission in the Real World Results From TARGET-IBD
Read more →2024 · Abstract/Manuscript · Harvard T.H. Chan School of Public Health
Use of tenofovir-based PrEP among pregnant women in South Africa
Read more →2024 · Abstract/Manuscript · University of Alabama at Birmingham
Comparing PCSK9 Monoclonal Antibody Treatment Strategies Following Myocardial Infarction Using Negative Control Outcomes: A Target Trial Emulation Study
Read more →2024 · Poster Presentation · AbbVie Inc. · Dermatology
Persistent Inadequate Disease Control and Therapeutic Inertia in Moderate-to-Severe Atopic Dermatitis: A 12-month Longitudinal Analysis of Real-world Outcomes from the TARGET-DERM AD registry (Fall Clinical 2024)
Read more →2024 · Poster Presentation · AbbVie Inc. · Dermatology
Impact of Therapeutic Inertia on Patient-Reported Outcomes in Moderate-to-Severe Atopic Dermatitis: A 12-Month Longitudinal Study from the TARGET-DERM AD Registry (RAD Winter 2023)
Read more →2023 · Poster Presentation · University of Birmingham / NIHR Birmingham BRC · Hepatology
NASH Progression Rates Based on Fibrosis and Inflammation (NAS): A Paired Biopsy Analysis From a Natural History Cohort in the US
Read more →2023 · Poster Presentation · Cleveland Clinic · Hepatology
A Prospective, Pragmatic Post-Authorisation Safety Study of Early Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus-Infected Patients after Direct-Acting Antiviral (DAA) Therapy: DAA-PASS
Read more →2023 · Poster Presentation · AbbVie Inc. · Dermatology
Persistent Inadequate Disease Control and Therapeutic Inertia in Moderate-to-Severe Atopic Dermatitis: A 12-month Longitudinal Analysis of Real-world Outcomes from TARGET-DERM registry (RAD Winter 2023)
Read more →2023 · Poster Presentation · University of Chicago · Gastroenterology
Outcomes of early vs. delayed advanced therapy among patients with moderate ulcerative colitis in the United States: TARGET-IBD
Read more →2023 · Poster Presentation · University of North Carolina at Chapel Hill · Gastroenterology
Treatment Journey among patients with moderate ulcerative colitis in the United States: TARGET-IBD
Read more →2023 · Poster Presentation · University of Birmingham (UK) · Methods/Pharmacoepi
Analysis of discrimination and calibration of two cardiovascular risk scores in patients with non-alcoholic steatohepatitis shows a need for improved accuracy of these models
Read more →2023 · Abstract/Manuscript · National University Hospital
Validation of a Clinical Risk-based Classification System in a Large Nonalcoholic Fatty Liver Disease Real-world Cohort
Read more →2023 · Abstract/Manuscript · Mayo Clinic
Impact of itch on quality of life in people with primary biliary cholangitis: a plain language summary
Read more →2023 · Oral Presentation · Hepatology
Non-alcoholic Steatohepatitis Disease Progression in Participants from the United States TARGET-NASH Real World Longitudinal Observational Study
Read more →2023 · Abstract/Manuscript · Northwestern University
Prevalence and burden of atopic dermatitis involving the head, neck, face, and hand: A cross sectional study from the TARGET-DERM AD cohort
Read more →2023 · Abstract/Manuscript · UCSD
Do Atopic Dermatitis Patient-Reported Outcomes Correlate With Validated Investigator Global Assessment? Insights From TARGET-AD Registry
Read more →2023 · Abstract/Manuscript · University of North Carolina at Chapel Hill
Prevalence of Immunomodulator Use as Combination Therapy With Vedolizumab or Ustekinumab in Inflammatory Bowel Disease
Read more →2023 · Abstract/Manuscript · University of North Carolina at Chapel Hill
Effectiveness of Remdesivir Treatment Protocols Among Patients Hospitalized with COVID-19: A Target Trial Emulation
Read more →2023 · Abstract/Manuscript · University of North Carolina at Chapel Hill
When Emulating a Trial, Do as the Trialists Do: Missteps in Estimating Relative Effectiveness of a Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Booster Dose
Read more →2023 · Abstract/Manuscript · Harvard T.H. Chan School of Public Health
Adherence to daily, oral TDF/FTC PrEP during periconception among HIV-exposed South African women
Read more →2023 · Abstract/Manuscript · Harvard T.H. Chan School of Public Health
High PrEP uptake and objective longitudinal adherence among HIV-exposed women with personal or partner plans for pregnancy in rural Uganda: A cohort study
Read more →2023 · Oral Presentation · Harvard T.H. Chan School of Public Health · Methods/Pharmacoepi
HIV risk perception and PrEP adherence among South African women planning for pregnancy and participating in STI screening
Read more →2022 · Poster Presentation · Saint Louis University · Hepatology
The Role of Disease Severity and Gender in Polypharmacy Among Patients with NAFLD Enrolled in TARGET-NASH
Read more →2022 · Poster Presentation · Novartis · Hepatology
Longitudinal ALT Trajectories are Generally Stable Among Patients with Non-Alcoholic Fatty Liver Disease (NAFLD): An Investigation Using Artificial Recurrent Neural Networks
Read more →2022 · Poster Presentation · AbbVie Inc. · Dermatology
Epidemiology and Burden of Atopic Dermatitis Involving the Head, Neck, Face, and Hand: a Cross Sectional Study from the TARGET-DERM AD Cohort (RAD 2021)
Read more →2022 · Poster Presentation · University of Chicago · Gastroenterology
The Impact of Early vs. Late Biologic Initiation Among Real World Patients with Crohn's Disease in TARGET IBD
Read more →2022 · Poster Presentation · Bristol Myers Squibb · Gastroenterology
Treatment patterns among moderate-to-severe ulcerative colitis patients in TARGET-IBD
Read more →2022 · Poster Presentation · University of Colorado Anschutz Medical Campus · Gastroenterology
Inflammation on Index Biopsy Predicts Loss of Remission Among Ulcerative Colitis Patients with Endoscopic Remission: a US Cohort Analysis
Read more →2022 · Poster Presentation · Methods/Pharmacoepi
Healthcare Utilization and Charges Associated with US Hospitalized Adult Patients with COVID 19
Read more →2022 · Poster Presentation · Methods/Pharmacoepi
Association Between Clinical Outcomes and Patient Characteristics Among Hospitalized Adult Patients with COVID-19
Read more →2022 · Abstract/Manuscript · Emory
Variation in Alanine Aminotransferase in Children with Non-Alcoholic Fatty Liver Disease
Read more →2022 · Abstract/Manuscript · Mayo Clinic
Impact of Pruritus on Quality of Life and Current Treatment Patterns in Patients with Primary Biliary Cholangitis
Read more →2022 · Abstract/Manuscript · Northwestern University
Real-world evidence on atopic dermatitis: Baseline characteristics and predictors of treatment choice in the TARGET cohort
Read more →2022 · Abstract/Manuscript · Atrium Health
Objective disease activity assessment and therapeutic drug monitoring prior to biologic therapy changes in routine inflammatory bowel disease clinical practice: TARGET-IBD
Read more →2022 · Abstract/Manuscript · University of North Carolina at Chapel Hill
Postpartum Medicaid enrollment and churn in North Carolina
Read more →2022 · Oral Presentation · Botswana Ministry of Health and Wellness · Methods/Pharmacoepi
HIV Incidence in Botswana Rural Communities With High Antiretroviral Treatment Coverage: Results From the Botswana Combination Prevention Project, 2013-2017
Read more →2022 · Oral Presentation · Brigham and Women's Hospital · Methods/Pharmacoepi
Health Impact and Cost-Effectiveness of HIV Testing, Linkage, and Early Antiretroviral Treatment in the Botswana Combination Prevention Project
Read more →2022 · Oral Presentation · Hepatology
Pruritus in Primary Biliary Cholangitis is Under-Treated in Clinical Practice: Results from TARGET-PBC (APASL)
Read more →2022 · Oral Presentation · Hepatology
The Pervasive Impact of Pruritus on Quality of Life in Patients with Primary Biliary Cholangitis (PBC): Real World Experience in TARGET-PBC (APASL)
Read more →2021 · Poster Presentation · AbbVie · Hepatology
Determination of Optimal Thresholds for Significant Fibrosis in NAFLD Using Non-Invasive Tests from TARGET-NASH Study
Read more →2021 · Poster Presentation · University of North Carolina at Chapel Hill · Gastroenterology
Histological Inflammation Predicts Loss of Remission Among Crohn's Patients with Endoscopic Remission: A US Cohort Analysis
Read more →2021 · Poster Presentation · University of North Carolina at Chapel Hill · Gastroenterology
Immunomodulators are Commonly Used as Concomitant Therapy with Vedolizumab or Ustekinumab: TARGET-IBD Real World Cohort
Read more →2021 · Poster Presentation · AbbVie Inc. · Gastroenterology
Biologic-naïve Patients with Crohn's Disease are More Likely to Achieve Mucosal Healing than Biologic-experienced Patients: TARGET-IBD Real World Cohort
Read more →2021 · Abstract/Manuscript · Heinrich Heine University Düsseldorf
Liver Biopsy in the Real World—Reporting, Expert Concordance and Correlation with a Pragmatic Clinical Diagnosis
Read more →2021 · Abstract/Manuscript · Heinrich Heine University Düsseldorf
Prevalence and Factors Associated With Statin Use Among Patients With Nonalcoholic Fatty Liver Disease in the TARGET-NASH Study
Read more →2021 · Abstract/Manuscript · University of Michigan
Patient Determinants for Histologic Diagnosis of NAFLD in the Real World: A TARGET-NASH Study
Read more →2021 · Abstract/Manuscript · University of Michigan
Weight Loss and Weight Regain in Usual Clinical Practice: Results from the TARGET-NASH Observational Cohort
Read more →2021 · Abstract/Manuscript · Zucker School of Medicine at Hofstra
Safety and Effectiveness of Tenofovir Alafenamide in Usual Clinical Practice Confirms Results of Clinical Trials: TARGET-HBV
Read more →2021 · Abstract/Manuscript · Atrium Health
Older Adult Patients Use More Aminosalicylate Monotherapy Compared With Younger Patients With Inflammatory Bowel Disease
Read more →2021 · Abstract/Manuscript · University of Chicago
Methodology and initial results from a real-world observational cohort of patients with inflammatory bowel disease: TARGET-IBD
Read more →2021 · Abstract/Manuscript · Amgen Inc.
Effectiveness and Safety of Romiplostim Among Patients with Newly Diagnosed, Persistent and Chronic Immune Thrombocytopenia in European Clinical Practice
Read more →2021 · Abstract/Manuscript · University of North Carolina at Chapel Hill
Medicaid Coverage Disruptions Among Children Enrolled in North Carolina Medicaid From 2016 to 2018
Read more →2021 · Abstract/Manuscript · University of North Carolina at Chapel Hill
Factors Associated with Readmission in the US Following Hospitalization with COVID-19
Read more →2020 · Poster Presentation · University of Miami (FL) · Hepatology
A Pragmatic Clinical Prognostic Classification Suitable for Universal Application Stratifies Patients with NAFLD by Risk of Mortality and Both Hepatic and Extrahepatic Outcomes
Read more →2020 · Poster Presentation · Heinrich-Heine University Düsseldorf · Hepatology
Heterogeneous Documentation and Poor Concordance of NASH Pathology May Limit its Clinical Utility in Real-World Practice
Read more →2020 · Poster Presentation · UNC · Hepatology
Fibrosis Assessed by Non-Invasive Tests is Similar to Liver Biopsy for Predicting Clinical Outcomes: A TARGET-NASH Study
Read more →2020 · Poster Presentation · Atrium Health · Gastroenterology
Factors Associated with Biologic Discontinuation in Patients with Inflammatory Bowel Disease in TARGET-IBD
Read more →2020 · Abstract/Manuscript · University of Michigan
A Real-World Observational Cohort of Patients with Hepatocellular Carcinoma: Design and Rationale for TARGET-HCC
Read more →2020 · Oral Presentation · Hepatology
Clinical Profile of Nonalcoholic Fatty Liver Disease in Adults with Type 2 Diabetes Mellitus
Read more →2020 · Abstract/Manuscript · Amgen Inc.
Treatment Patterns Among Adults with Primary Immune Thrombocytopenia Diagnosed in Hematology Clinics in the United States
Read more →2020 · Abstract/Manuscript · University of Alabama at Birmingham
Lipid Testing Trends in the US Before and After the Release of the 2013 Cholesterol Treatment Guidelines
Read more →2020 · Abstract/Manuscript · University of North Carolina at Chapel Hill
Patient Characteristics and Outcomes of 11,721 Patients with COVID19 Hospitalized Across the United States
Read more →2020 · Oral Presentation · Gastroenterology
Objective Disease Activity Assessment and Therapeutic Drug Monitoring is Lacking Prior to Biologic Therapy Changes in Routine Inflammatory Bowel Disease Clinical Practice: TARGET-IBD
Read more →2020 · Poster Presentation · Atrium Health · Gastroenterology
Medication Use and Comorbidities Among Elderly as Compared to Younger Patients with Inflammatory Bowel Disease in the TARGET-IBD Cohort (ACG)
Read more →2019 · Poster Presentation · University of Pennsylvania · Methods/Pharmacoepi
Factors Associated with Readmission Following COVID-19 Hospitalization
Read more →2018 · Poster Presentation · Stanford · Hepatology
Primary Biliary Cholangitis (PBC) in the U.S.: Real World Effectiveness of Obeticholic Acid in TARGET-PBC (DDW)
Read more →2018 · Poster Presentation · Stanford · Hepatology
Primary Biliary Cholangitis (PBC) in the U.S.: Clinical Characteristics of Patients Enrolled in TARGET-PBC (DDW)
Read more →2018 · Abstract/Manuscript
A Real-World Observational Cohort of Patients with Primary Biliary Cholangitis: TARGET-PBC Study Design and Rationale
Read more →2018 · Abstract/Manuscript · University of North Carolina at Chapel Hill
Initiation and interruption in intravenous bisphosphonate therapy among patients with multiple myeloma in the United States
Read more →2018 · Abstract/Manuscript · University of North Carolina at Chapel Hill
Use of bone-modifying agents among breast cancer patients with bone metastasis: evidence from oncology practices in the US
Read more →2017 · Poster Presentation · University of Michigan · Hepatology